Related Experiment Video
Updated: Jun 2, 2026

The Use of Flow Cytometry to Assess the State of Chromatin in T Cells
Published on: December 17, 2015
Control of cell cycle regulatory proteins and modulation of STAT1 proteins by IFN-gamma in human prostatic JCA-1
1NEW YORK MED COLL,DEPT BIOCHEM & MOL BIOL,VALHALLA,NY 10595. NEW YORK MED COLL,DEPT UROL,VALHALLA,NY 10595.
Abstract:
The addition of human recombinant IFN-gamma (10(2) and 10(3) IU/ml) inhibited human prostatic JCA-1 cell growth by 27% and 64%, respectively. Since the high dose of IFN-gamma elicited an increase in G(1) concomitant with a decrease in G(2)/M phases of the cell cycle, changes in the expression of cell cycle regulatory protein molecules were analyzed by Western blots. Results of these experiments show that IFN-gamma down regulated the G(1)/S transition molecules, e.g., cyclin D1, the cyclin-dependent protein kinase Cdk4, and the retinoblastoma gene product (pRB), but increased the G(2)/M transition molecules, e.g., cyclin B1 and p34(cdc2) (Cdk1). Possible modulation of Cdk-inhibitors (CDKIs), e.g., p53 and p21(WAF1), which have checkpoint functions in the cell cycle, by IFN-gamma, was also studied. The p53 was induced by both 10(2) and 10(3) IU/ml IFN-gamma. At 10(3) IU/ml, IFN-gamma inhibited p21(WAF1), increased the expression of STAT1 alpha, and sustained the elevated STAT1 alpha for up to 96 h. Thus several mechanisms may be involved in the antiproliferative effects of IFN-gamma.
Insights
Human recombinant interferon-gamma (IFN-gamma) significantly inhibits prostate cancer cell growth by altering cell cycle regulation. IFN-gamma affects key proteins controlling cell cycle progression and activates STAT1 alpha, contributing to its antiproliferative effects.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Prostate cancer remains a significant health concern.
- Interferon-gamma (IFN-gamma) is a cytokine with known immunomodulatory and antiproliferative properties.
- Understanding the molecular mechanisms of IFN-gamma's effects on prostate cancer cells is crucial for therapeutic development.
Purpose of the Study:
- To investigate the antiproliferative effects of human recombinant IFN-gamma on JCA-1 human prostate cancer cells.
- To elucidate the impact of IFN-gamma on cell cycle progression and the expression of related regulatory proteins.
Main Methods:
- Cell growth inhibition assays using JCA-1 cells treated with varying doses of IFN-gamma.
- Cell cycle phase analysis (G1 and G2/M) following IFN-gamma treatment.
- Western blot analysis to assess the expression levels of cell cycle regulatory proteins (cyclins, CDKs, CDKIs) and STAT1 alpha.
Main Results:
- IFN-gamma inhibited JCA-1 cell growth in a dose-dependent manner (27% at 10^2 IU/ml, 64% at 10^3 IU/ml).
- High-dose IFN-gamma treatment led to G1 cell cycle arrest and decreased G2/M phase.
- IFN-gamma modulated cell cycle proteins, downregulating G1/S transition molecules (cyclin D1, Cdk4, pRB) and upregulating G2/M transition molecules (cyclin B1, p34(cdc2)).
- IFN-gamma induced p53 expression and inhibited p21(WAF1) at higher doses.
- IFN-gamma increased and sustained STAT1 alpha expression.
Conclusions:
- IFN-gamma exhibits significant antiproliferative effects on human prostate cancer cells.
- The antiproliferative action of IFN-gamma involves complex modulation of cell cycle regulatory proteins.
- Activation of STAT1 alpha and alterations in cell cycle checkpoints likely contribute to IFN-gamma's therapeutic potential in prostate cancer.
Related Concept Videos
The JAK-STAT Signaling Pathway
Inhibition of Cdk Activity
Inhibition of CDK Activity
Negative Regulator Molecules
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
The Cell Cycle Control System

